Crystagen

What Crystagen is, structurally

Crystagen is a tripeptide with a free N-terminal amine and a C-terminal proline bearing a free acid.

The formula reconciles exactly. Three nitrogens means three backbone amides and nothing else, none of the three residues carrying a side-chain nitrogen. The eight oxygens divide as two backbone carbonyls, two for the terminal acid, and four across the acidic side chains.

Charge is strongly negative. Two acidic side chains and the C-terminal acid give three carboxylates against a single N-terminal amine, with no basic residue anywhere. The peptide is highly polar and freely water soluble, though no quantitative figure is quoted here.

Two positions carry chemistry the composition alone would not reveal, and they sit at opposite ends.

The glutamate is at the N-terminus, where its side chain and the free alpha-amine can close a five-membered ring, converting the residue to pyroglutamate. That is specific to glutamate or glutamine in the first position.

The aspartate is followed by proline, and that pair is the most acid-labile linkage in ordinary peptide chemistry. It also closes off a route most aspartates carry, for reasons set out under storage.

There is no cysteine, no methionine and no aromatic residue.

Reconstitution and handling

Sterile water is the default solvent, and with no metal centre present PBS or an appropriate assay buffer are equally suitable. Add diluent down the vial wall, swirl gently, and let it stand until clear. Vortexing only introduces foaming.

Do not reach for an acidic diluent. The aspartyl-prolyl bond hydrolyses far faster in mild acid than an ordinary peptide bond does, and a peptide this polar has no need of acid to dissolve. Near-neutral preparation avoids the issue entirely.

Adsorption onto plasticware is worth allowing for at low concentration, and low-protein-binding tubes reduce measured loss, though a small strongly anionic peptide has limited affinity for polypropylene.

This is laboratory preparation chemistry, not dosing, administration, or protocol guidance of any kind.

Storage and stability

Store the lyophilized powder at -20 degrees C, sealed, desiccated and protected from light, and let a cold vial warm before opening. Reconstituted, hold at 2 to 8 degrees C, or aliquot and freeze rather than thawing repeatedly.

Two liabilities are open to this sequence, and a third that would normally apply is not.

The aspartyl-prolyl bond is the more consequential. In mild acid it cleaves considerably faster than an ordinary peptide bond, splitting the molecule in two, which is why acid is worth avoiding at every stage rather than only in storage.

The N-terminal glutamate is the second. Its side chain closes onto its own alpha-amino group, giving pyroglutamate and releasing water. The product is eighteen units lighter and carries one fewer free amine, so it is both lighter and less basic. Warmth accelerates it.

What is not available is the isoaspartate rearrangement. It needs the following residue's backbone nitrogen to attack the aspartate side chain, and that nitrogen must bear a hydrogen. Proline's is tertiary and has none, so the route is closed. The same proline that makes this acid-sensitive protects it from the rearrangement most aspartate-containing peptides undergo.

Cold, dry and firmly near-neutral covers both of the routes that are open.

How Crystagen is tested

Reversed-phase HPLC establishes chromatographic purity as area percent. With no aromatic residue there is no 280 nm absorbance, so detection sits near 214 nm. The peptide is small and strongly anionic, so it retains weakly on a standard C18 column and elutes early.

One method caution follows. Peptide methods commonly use trifluoroacetic acid as an ion-pairing additive, making the mobile phase acidic, and an aspartyl-prolyl bond can cleave during the run rather than before it. Prompt injection matters more here than usual.

Area percent is a chromatographic measure rather than peptide content by weight. On a 359 g/mol peptide the counter-ion is a proportionally large share of the vial contents.

Mass spectrometry distinguishes the two degradation routes cleanly, since they leave different signatures. Pyroglutamate formation is a loss of eighteen, giving a species at 341.31. Acid cleavage produces two smaller fragments rather than a shifted parent. Neither is isobaric with the intact peptide, so both are visible by mass, which is not true of most aspartate-containing sequences.

Handling FAQ

Why avoid acidic conditions specifically? Because of the aspartate-proline bond. That linkage hydrolyses much faster in mild acid than a normal peptide bond, so an acidic diluent, or a long standing time in acidic mobile phase, can cleave the molecule. Near-neutral handling avoids it.

Does the aspartate make this prone to isoaspartate formation? No. The rearrangement needs the following residue's backbone nitrogen to bear a hydrogen, and proline's does not. The route is closed rather than merely slow, which is unusual for an aspartate-containing sequence.

Full specifications for Crystagen.